ArticleIranian journal of pharmaceutical research : IJPR2015
Preparation and characterization of rifampin loaded mesoporous silica nanoparticles as a potential system for pulmonary drug delivery.
Article in Iranian journal of pharmaceutical research : IJPR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Quality by design based ecofriendly HPLC analytical method for simultaneous quantification of erastin and lenalidomide in mesoporous silica nanoparticles.Scientific reports · 2025Article
- Rifampin-loaded Mesoporous Silica Nanoparticles Improved Physical and Mechanical Properties and Biological Response of Acrylic Bone Cement.Journal of medical signals and sensors · 2025Article
- Rifampicin adsorption and release study using Santa Barbara amorphous-16 modified Al (SBA-16-Al) for a drug delivery system.RSC advances · 2024Article
- Evaluation of chlorophyll-loaded mesoporous silica nanoparticles for photodynamic therapy on cancer cell lines.Lasers in medical science · 2024Article
- Fabrication and characterization of apremilast-loaded zinc oxide-mesoporous silica nanoparticles for psoriasis treatment.Therapeutic delivery · 2024Article
- Polymeric nanocomposite hydrogel scaffold for jawbone regeneration: The role of rosuvastatin calcium-loaded silica nanoparticles.International journal of pharmaceutics: X · 2023Article
- Enzyme and Thermo Dual-stimuli Responsive DOX Carrier Based on PNIPAM Conjugated Mesoporous Silica.Iranian journal of pharmaceutical research : IJPR · 2022Article
- Preparation, characterization, and in-vitro cytotoxicity of nanoliposomes loaded with anti-tubercular drugs and TGF-β1 siRNA for improving spinal tuberculosis therapy.BMC infectious diseases · 2022Article
- In Vitro Study to Evaluate the Efficacy of Ultrasonicated Ethanolic Extract of Rosmarinus officinalis and its Chitosan-Based Nanoparticles Against Eimeria tenella Oocysts of Chickens.AAPS PharmSciTech · 2022Article
- Mesoporous silica nanocarriers as drug delivery systems for anti-tubercular agents: a review.Royal Society open science · 2022Review
- Dual Stimuli-Responsive Multifunctional Silicon Nanocarriers for Specifically Targeting Mitochondria in Human Cancer Cells.Pharmaceutics · 2022Article
- How Advancing are Mesoporous Silica Nanoparticles? A Comprehensive Review of the Literature.International journal of nanomedicine · 2022Review
- Adsorption and Release of Sulfamethizole from Mesoporous Silica Nanoparticles Functionalised with Triethylenetetramine.International journal of molecular sciences · 2021Article
- Mesoporous Silica Particles as Drug Delivery Systems-The State of the Art in Loading Methods and the Recent Progress in Analytical Techniques for Monitoring These Processes.Pharmaceutics · 2021Review
- Synthesis and Characterization of Mesoporous Mg- and Sr-Doped Nanoparticles for Moxifloxacin Drug Delivery in Promising Tissue Engineering Applications.International journal of molecular sciences · 2021Article
- A comparative pharmacokinetic study of a novel sustained release danofloxacin formulation and the conventional product in rabbits.Veterinary research forum : an international quarterly journal · 2021Article
- Synthesis and characterization of antibacterial drug loaded β-tricalcium phosphate powders for bone engineering applications.Journal of materials science. Materials in medicine · 2020Article
- Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2020Review
- Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections.Antibiotics (Basel, Switzerland) · 2019Article
- Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances.Pharmaceutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of this research is to determine the feasibility of loading rifampin into mesoporous silica nanoparticles. Rifampin was selected as a model lipophilic molecule since it is a well-documented and much used anti tuberculosis drug. The mesoporous silica nanoparticles were prepared by using tetraethyl ortho silicate and cetyltrimethyl ammonium bromide (as surfactant). The prepared nanoparticles were characterized in terms of their particle size measurement and porosimetry. The results showed that the particle size is 218 ± 46 nm (mean ± SD) and surface area is 816 m(2)g(-1). In order to load rifampin within the mesopores, adsorption experiments using three different solvents (methanol, water and dimethyl sulfoxide) were carried out. The loading procedure resulted in a significant improvement in the amount of rifampin loaded into mesoporous silica nanoparticles and methanol was found to be a suitable solvent, providing a drug entrapment efficiency of 52 %. Rifampin loaded nanoparticles underwent different in-vitro tests including, SEM and drug release. The in-vitro drug release was investigated using buffer phosphate (pH=7.4). Regarding the drug release study, a biphasic pattern of release was observed. The drug-loaded mesoporous silica nanoparticles were capable of releasing 95% of their drug content after 24 h, following a faster release in the first four hours. The prepared rifampin loaded nanoparticles seem to have potential for use as a pulmonary drug delivery.
Indexed as
Identifiers
25561909PMC4277616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.